Pulmonary embolism: A complication of COVID 19 infection.
Adult
Aged
Anticoagulants
/ therapeutic use
Betacoronavirus
/ isolation & purification
COVID-19
Coronavirus Infections
/ complications
Enoxaparin
/ therapeutic use
Female
Fibrinolytic Agents
/ therapeutic use
Humans
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ complications
Pulmonary Embolism
/ diagnosis
Pyrazoles
/ therapeutic use
Pyridones
/ therapeutic use
Rivaroxaban
/ therapeutic use
SARS-CoV-2
Tissue Plasminogen Activator
/ therapeutic use
Anticoagulation
COVID 19
Pulmonary embolism
Thrombolysis
Journal
Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
24
04
2020
revised:
19
05
2020
accepted:
22
05
2020
pubmed:
12
6
2020
medline:
18
9
2020
entrez:
12
6
2020
Statut:
ppublish
Résumé
The Coronavirus Disease 2019 (COVID 19) has been reported in almost every country in the world. Although a large proportion of infected individuals develop only mild symptoms or are asymptomatic, the spectrum of the disease among others has been widely variable in severity. Additionally, many infected individuals were found to have coagulation markers abnormalities. This is especially true among those progressing to severe pneumonia and multi-organ failure. While the incidence of venous thromboembolic (VTE) disease has been recently noted to be elevated among critically ill patients, the incidence among ambulatory and non-critically ill patients is not yet clearly defined. Herein, we present six patients who didn't have any hypercoagulable risk factors yet presented with pulmonary embolism in association with COVID 19 infection. Furthermore, we discuss the possible underlying mechanisms of hypercoagulability and highlight the possibility of underdiagnosing pulmonary embolism in the setting of overlapping symptoms, decreased utilization of imaging secondary to associated risks, and increased turnover times. In addition, we emphasize the role of extended thromboprophylaxis in discharged patients.
Identifiants
pubmed: 32526545
pii: S0049-3848(20)30205-X
doi: 10.1016/j.thromres.2020.05.033
pmc: PMC7247481
pii:
doi:
Substances chimiques
Anticoagulants
0
Enoxaparin
0
Fibrinolytic Agents
0
Pyrazoles
0
Pyridones
0
apixaban
3Z9Y7UWC1J
Rivaroxaban
9NDF7JZ4M3
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Case Reports
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-82Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors report no conflict of interests.
Références
Open Forum Infect Dis. 2016 Dec 20;3(4):ofw214
pubmed: 28018924
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
Thromb Haemost. 2000 Aug;84(2):319-24
pubmed: 10959707
Eur Heart J. 2019 Nov 1;40(42):3453-3455
pubmed: 31697840
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Circ Res. 2016 Apr 29;118(9):1392-408
pubmed: 27126649
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Vasc Surg Venous Lymphat Disord. 2019 May;7(3):317-324
pubmed: 30477976
N Engl J Med. 2018 Sep 20;379(12):1118-1127
pubmed: 30145946
N Engl J Med. 2016 Aug 11;375(6):534-44
pubmed: 27232649